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Benzodiazepines are commonly used as the first line treatment for adults diagnosed with 
Generalized Anxiety Disorder (GAD) despite clinical guidelines that recommend otherwise. This 
can lead to misuse, abuse, addiction, and dependence. To de-escalate use of benzodiazepines as 
first-line treatment, this DNP Project seeks to reinforce use of evidence-based practice via a 
reminder card. The guideline compliance program was assessed by chart review to determine 
impact on GAD-7 scores and benzodiazepine prescriptions. Total of 69 patients’ charts were 
audited by six prescribers, over the period of eight weeks, to determine if outcomes were met.  
When analyzed pre and post intervention on GAD-7 scores, a paired sample t-test demonstrated 
a p -value of <0.001 which indicated that statistical significance was met.  Reinforcement of 
clinical guidelines via a reminder card resulted in reduction scored on GAD-7 and number of the 
benzodiazepine prescriptions.  All patients (N=69) were offered the opportunity to de-escalate 
benzodiazepine use by decreasing doses, alternative medications, psychotherapy or were 
prescribed medications according to guidelines that promoted decrease in benzodiazepine use.  
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 Benzodiazepines are beneficial class of drugs in treating anxiety. However, there are 
trends indicating a significant public health problem related to benzodiazepines misuse. For 
instance, Maust et al. (2020) noted that 30.6 million adults, which accounts for 12.6% of the 
entire population used benzodiazepine. It is estimated that 25.3 million (10.4%) adults were 
taking it as prescribed, while 5.3 million (2.2%) adults were misusing the medication. Further, 
the highest misuse (5.2%) was among persons aged 18 to 25 years old. This public health 
challenge is heightened by the fact that abuse, misuse and dependent on stimulants and opioids is 
significantly associated with benzodiazepine misuse. Benzodiazepines are most accessed without 
a prescription from a friend or family member. This issue is further exacerbated by the absence 
of a collective consensus among medical experts on the diagnostic criterion which should be 
satisfied to warrant a benzodiazepine prescription (Silberman et al., 2021).        
The federal government has taken several measures to address drug abuse. For instance, 
according to the Drug Enforcement Agency (2020), the federal government enacted the 
Controlled Substances Act (CSA) which regulates production and distribution of the substances’ 
accepted medical use, potential for abuse, and safety or dependence liability. However, 
implementing this act and other measures by the Department of Health and Human Services 
(HHS) has not been effective. This can partly be attributed to insufficient data on drug utilization 
behaviors and problems associated with recommending relatively high doses of benzodiazepines 
has also impeded efforts to appropriately conduct comparative drug consumption within the 
United States (Lembke et al., 2018).  
According to Samardzic and Svob Strac (2016), benzodiazepine abuse is associated with 
physical effects such as poor coordination, loss of visuo-spatial ability, irritability, sleep 
disturbances, and continual drowsiness. Extreme cases of benzodiazepine abuse may also result 
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in an emergency room (ER) visit and even death. Prolonged use of benzodiazepine among 
persons with anxiety and related disorder may exacerbate health conditions by leading to 
increased anxiety (Hayhoe & Lee-Davey, 2018). This reinforces the need to de-escalate 
benzodiazepine use. 
De-escalating the use of benzodiazepines for adults is crucial in concerted health 
promotion initiatives to promote the appropriate use of the medication, prevent harm from abuse, 
and improve patient outcomes (Suss & Oldani 2020). Healthcare providers particularly 
pharmacist, nurses and physicians play a significant role in promoting proper use of and in de-
escalation among patients with anxiety who have misused the drug (Platt et al., 2021). This is 
achieved by implementing evidenced based practice guidelines that will reduce potential for 
benzodiazepine misuse and abuse. In this regard, this project aims to remind providers to offer 
de-escalation where appropriate and reduce escalation by following treatment recommendations. 
 Background 
  According to the DSM-V (2013) guidelines, Generalized Anxiety Disorder (GAD) is 
classified as excessive anxiety and worrying that has occurred for a minimum of six months 
relating to activities of daily living. The anxiety presents with symptoms equivalent to restless 
leg, fatigue, trouble concentrating, irritability, disturbed sleeping, and muscle tension (Simon et 
al., 2021). Health providers are likely to find it challenging to diagnose GAD accurately. 
Undoubtedly, this created the need for reliable, efficient, and exhaustive screening tools. One 
such screening tool is the Generalized Anxiety Disorder scale-7 (GAD-7); a 7-item diagnostic 
tool validated in the general population and primary care settings (Sapra et al., 2020). There are 
also other multiple scales for screening GAD, including Hamiliton Anxiety Scale (HAM-A), 
Covi Anxiety Scale, Hospital Anxiety and Depression Scale (HADS), and State-Trait Anxiety 
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Inventory (STAI), among others (Sapra et al., 2020). After patients are identified to have GAD 
using some of these screening tools, health providers usually go for thyroid function tests before 
prescribing any antidepressant. Assessment of thyroid function might is an ideal predictor in the 
treatment of GAD (Bathla, Singh, & Relan, 2016). 
There are various non-pharmacological and pharmacologic recommendations for patients 
diagnosed with GAD. The treatment recommendations involve psychological therapy or 
pharmacotherapy, or a combination of the two. A non-pharmacologic treatment, such as 
cognitive-behavioral therapy (CBT), is among the preferred first-line treatments (Bandelow, 
Michaelis, & Wedekind, 2017). Other non-pharmacologic therapies include behavioral 
techniques, supportive psychotherapy, and insight-oriented psychotherapy (Gautam et al., 2017). 
The recommended first-line drugs include selective reuptake inhibitors and serotonin-
norepinephrine reuptake inhibitors, while benzodiazepines are not recommended for routine use. 
Additional pharmacologic treatments alternatives include buspirone, tricyclic antidepressants, 
moclobemide, and pregabalin. When developing a treatment plan for patients with GAD, it is 
vital to consider efficacy, costs, interactions, and adverse effects (Bandelow et al., 2017).     
Pharmacologic intervention should be considered in patients whose anxiety disorder 
impairs activities of daily living and functioning (Lader, 2019). One of the second-line 
prescribed groups of medicines for patients with anxiety is benzodiazepines. The behavioral 
impact of benzodiazepines has been compared to the impact of high doses of barbiturates on the 
body (Lader, 2019). Benzodiazepines are a class of prescription medication that binds to the 
GABAA receptor, resulting in hypnotic, muscle-relaxing, anticonvulsant, and anxiolytic effects.  
As such benzodiazepines are classified as central nervous system depressant drugs that are used 
to treat acute alcohol withdrawal, depression, insomnia, excitation, aggressiveness, panic, 
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phobias, anxiety and seizure among others (Lader, 2019). Traditionally, benzodiazepines are 
illustrious for their sedative-hypnotic effect, inducing muscle relaxation, and causing an overall 
reduction in levels of anxiety. However, it's worth noting that patients taking benzodiazepines 
are highly likely to experience the “withdrawal rebound phenomenon” related to the 
drug (Peppin et al., 2020). A pattern of physical dependence among patients is emerging because 
of prolonged and uninhibited use of the drug.  The overall inability among patients with anxiety 
to successfully address the withdrawal effects is one of the first reasons why attention is turning 
to the long-term effects of prescribing.   
Lab experiments involving rats and dogs receiving doses of benzodiazepines have 
conjointly recorded similar results, further raising their side effect profile (Balon & Starcevic, 
2020).  It has been tested beyond any reasonable doubt that benzodiazepines produce physical 
dependencies and have a major impact on living organisms. Their reinforcing efficaciousness is 
higher in individuals who ultimately develop a physical dependence to the drug.  Benzodiazepine 
abuse often starts with patient’s prescribed drugs that later progress to taking more than the 
recommended doses before developing tolerance. Common withdrawal effects after minor 
tranquillizer cessation embody perceptual distortion, insomnia, coordination problems, and 
restlessness (Tyrer, 2019). These effects are particularly common among individuals blatantly 
abusing the drug or those on a restively high dose of the medication. Tolerance additionally 
fosters the need for higher doses for the drug to elicit an initial therapeutic effect. 
Practice Gap 
A consensus exists amongst professionals within the mental health care community that 
there is a comprehensible need for reprioritization of psychotherapeutic treatment interventions 
for addressing patient’s pathologies (Tyrer, 2019). Forward-thinking and evolving practice 
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pointers would likely experience clinically exceptional benefit(s) by transitioning to a care model 
that places emphasis on alternative evidence-based treatment interventions (i.e. use 
of pharmacological agents with a less habit-forming profile, properly encouraging patients 
regarding the perpetual need for implementing effective psychotherapeutic relaxation techniques 
and devotion to sleep hygiene as well as healthy balanced life style maintenance, etc.). Clinical 
literature also reiterates that benzodiazepines prescriptions, including Xanax, Ativan, Klonopin, 
and Valium, should seldom supersede a month length of treatment. Therefore, the use of BZDs 
in quantities and durations of time that surpass DSM-V standards should be restricted to 
situations whereby patients have severe refractory anxiety-based disorders. Aggregation of data 
and extrapolation of results shall transpire at psychiatric clinics or practices where patients for 
this research project will be evaluated. Through utilizing anxiety treatment tool, patients with 
will be able to choose a benzodiazepine-free treatment. 
Benzodiazepines should be prescribed in line with the Community Behavioral Health 
(2018) clinical guidelines for the prescribing and monitoring of benzodiazepines and related 
medications. However, this is not always the case and there is misuse which has significant 
negative effects. For instance, Lader (2019) mentioned that benzodiazepine abuse is likely to 
slow the processing of thoughts and verbal abilities, which are particularly common in persons 
recovering from these drugs.  Benzodiazepine misuse presents two main health effects namely 
withdrawal and overdose (Hirschtritt et al., 2021). In most cases, benzodiazepines are combined 
with other drugs and alcohol which increases risk of overdose mainly through cardiac arrhythmia 
or respiratory suppression. Further, prolonged misuse benzodiazepines increase tolerance where 
patients need more doses to obtain the same effect, withdrawal symptoms and use disorder 
(Lembke et al., 2018). Benzodiazepine dependence and withdrawal can start after only 4 to 6 
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weeks of use and affects 20% to 30% of persons with regular use. In adults, Benzodiazepine 
dependence increases chances of hip fractures falls, cognitive impairment, and drug-associated 
hospital admissions (Hirschtritt et al., 2021). 
The misuse of benzodiazepine has adverse effects on the patient’s family, health facility 
and generally society. For instance, increased admission raises healthcare costs for the patient 
and society as well (Samardzic & Svob Strac, 2016). Further, there is lost productivity which has 
adverse effects on the economy (Lembke et al., 2018). The patient’s family may be forced to 
take care of their kin, which has negative effects. This shows that this project which explores de-
escalation of benzodiazepine misuse will help in reduction of adverse health and financial effects 
on the patient, their family and wider society.  
The prevention of drug dependence goes a long way in managing substance abuse which 
impacts a considerable cross-section of individuals on prescription medication. Dependence on 
benzodiazepines is often associated with polysubstance abuse and likely to be fatal in the event if 
it is not effectively managed within an appropriate timeline (Jones, 2016). Research posits the 
notion that continued use of benzodiazepines is likely to serve as a gateway drug to heroin, 
methadone, and alcohol use among high-dose benzodiazepine abuse (Lader, 2019). These effects 
are particularly common among those individuals who are blatantly abusing the drug or those on 
a restively high dose of the medication. Tolerance also fosters the need for continued higher dose 
to elicit an initial therapeutic effect (loading dose).  Individuals with anxiety disorder represent 
an at-risk population due to their propensity to misuse prescribed benzodiazepines. The drug's 
rapid onset of action and mind-altering properties further increase the chances of inducing 
addiction. 
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At the clinic, which will serve as the project site, prescribing of benzodiazepines often 
deviates from standards of care. For patients who have been taking the medications in the long 
term, opportunities to de-escalate use are not routinely offered. Even though there is a significant 
number of patients prescribed benzodiazepines, providers at the project site fail to follow or 
deviate from guidelines for dose de-escalation, exposing patients to possible addiction. Health 
providers at the project site deviate from de-escalation guidelines due to limited time, patients' 
pressure for benzodiazepines, and providers not being updated on some recent evidence-based 
practice treatment (Psychiatric nurse practitioner, personal communication, June 2021). This 
DNP project seeks to address this practice gap by promoting guideline utilization to promote de-
escalation of benzodiazepine use in adults with generalized anxiety disorder.  For patients who 
are naive to the medications, providers must ensure that guidelines are followed to prevent the 
use or dose-escalation. 
Review of Major Clinical Guidelines 
 There are two major clinical guidelines used in the treatment of GAD. The first guideline 
is NICE. The other guidelines are APA.  
NICE 
The National Institute for Clinical Excellence, NICE (Clinical Guidelines for the 
Management of Anxiety, 2004) published guidelines on the management of panic disorder and 
GAD in Adults in Primary, Secondary and Community Care. The guideline suggests that before 
any medical prescriptions are made, psychological interventions such as Cognitive Behavioral 
Therapy (CBT) acts as the most effective intervention. For most patients, CBT sessions are 
suggested to be conducted weekly for one to two hours. These sessions ought to be completed 
within a thorough going of four months since the time of initiation. The guideline further 
suggests that the medical professional considers the age, previous treatment response, if any, 
13 
preference of the patient and the tolerability along with the risk of deliberate self-harm, observed 
in patient history before making a pharmacological intervention. 
Selective serotonin reuptake inhibitors (SSRIs) work with serotonin transporter and work 
by increasing the levels of serotonin in the brain by blocking its reabsorption in the neurons. 
They work by enhancing the functioning of the nerve cells in the brain that control emotion. 
Hence, these are prescribed as first line medications and are considered relatively safer and 
typically they cause lesser side effects than other medications, specifically BZD does. Serotonin–
norepinephrine reuptake inhibitors (SNRIs) are similar in function to SSRIs but they block or 
delay the reuptake of serotonin and norepinephrine in the brain. Stabilization of these 
neurotransmitters helps improve a person’s mood, relieve panic attacks and reduces the feeling 
of anxiety.  
The guideline recommends using SSRIs instead of BDZs as the preeminent choice of 
medication. An SSRI should be prescribed for a period of 12 weeks and if no visible 
improvement is observed, another SSRI should be prescribed. The guideline also recommends 
that BZDs should only be prescribed if SSRIs are not available or unsuitable and only if there is 
no improvement noticed from its use. This shows the level of caution which medical 
professionals should practice before prescribing BZD. Pharmacological therapy in the form of 
SSRI and self-help are long term interventions which the clinical guideline suggests having 
evidence of long-term duration effects.  
NICE suggests that before starting any antidepressant, the healthcare professional ought 
to always contemplate the side effects of starting the medication and hence prescribe lower 
dosages and slowly increase the dosage until satisfactory response from intervention is observed. 
When looking at comorbid levels of anxiety, SSRIs and/or SNRIs are the first-line medicated 
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interventions (Strawn, et al., 2018). The authors encourage considering age and co-morbidity in 
selection of psychopharmacologic treatments. He suggests that benzodiazepine may be 
prescribed as the second-line pharmacotherapies, however, SSRI, GAD, and SNRIs should be 
used as first-line psychopharmacologic treatment. Concerning pediatric patients with symptoms 
of GAD, SSRIs ought to be considered as the first line pharmacotherapy. The coupling if 
psychotherapy with pharmacotherapy augments the antidepressant response (Strawn, et al., 
2018). 
APA  
The American Psychiatric Association APA (APA, 2008) practice guideline for the 
treatment of patients with panic disorder suggests the use of tricyclic antidepressants (TCAs) in 
case SSRIs and SNRIs fail as first-line medications. Moreover, the guideline raises several 
concerns over benzodiazepine tolerance and withdrawal. The study even reports amplified risk of 
accident while driving a vehicle in association with benzodiazepine use.  
Both APA and NICE suggest the use of CBT alongside these medications and self-help 
modeled on CBT principles. Moreover, these guidelines also suggest appropriate dosages and 
prescription and since BDZs are associated with an unsatisfactory outcome in the long term, they 
should not be prescribed more than 2 to 4 weeks in GAD. However, it is important to understand 
that for panic disorders, benzodiazepines are not a suitable choice. 
  The International Psychopharmacology Algorithm Group (IPAP) released a 
psychopharmacological treatment algorithm for GAD (Davidson JR, et al 2010), in which they 
suggest a serial line of approach to the pharmacotherapy of GAD and recommend several 
approaches past the first level of treatment. The research guideline also agrees to prescription of 
SNRIs as second line pharmacotherapy intervention.   
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Literature also supports the prescription of BZDs for some patients at higher risk for 
abuse. Ciraulo et al. (2000) discussed Benzodiazepine treatment in substance abuse patients and 
concluded that if enough education on the risks of combining BZDs with alcohol or other 
intolerable substances, and if medical professional responsibly holds transparent discussion on 
diversion mechanisms and monitors for any adverse effects and misuse, then prescription of 
BZDs as first-line interventions can be made under special circumstances.  
El-Guebaly et al. (2010) discuss in detail the guidelines for the responsible prescription of 
benzodiazepines and conclude that physiological dependence depends mostly on the dosage and 
the duration of exposure. The study concluded that dependency can be reduced by intermittent 
exposure to BDZs as opposed to a continued exposure. If misuse of BZDs is identified in 
patients, the Canadian guidelines on benzodiazepine receptor agonist use disorder among adults 
suggest a patient centric and step by step care approach to gradually decrease the dosage of 
BZDs in the management of Benzodiazepine receptor agonist (BZRA) (Conn et al., 2020).  
AGREE II tool was used to determine the best clinical guideline to follow. The tool was 
developed by The Agree Enterprise Trust (2009). It is commonly utilized in the evaluation of the 
quality and reporting of clinical practice guidelines. The tool entails 23 key items classified into 
six major domains. The first domain is interested in the scope and purpose of the clinical 
guideline. The second domain focuses on stakeholder involvement (inclusion of health providers, 
target users, and patients). The rigor of development is the third domain, focusing on gathering 
and synthesizing available evidence utilized to develop the guideline (The Agree Enterprise 
Trust, 2009). Clarity of presentation, focusing on language, format, and structure of the given 
domain, is the fourth domain. The fifth domain is interested in applicability in relation to barriers 
and facilitators, approaches for enhancing uptake, and cost implications. The last domain focuses 
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on editorial independence, ensuring that the recommendations made in the guideline are not in 
any way biased because of competing interests (The Agree Enterprise Trust, 2009). Therefore, 
the tool will be applicable in this DNP project as the aim is to use the guideline to promote de-
escalation of benzodiazepine use in adults with GAD. The tool will help appraise if the clinical 
guideline followed by health providers is appropriate.  
Reconciling Best-Practices 
Potential Evidence-Based Solutions 
Several studies have been conducted on various aspects of benzodiazepine use, misuse 
and on measurers to address the health challenges posed by misuse of the drugs. For instance, 
Roy-Byrne (2015) conducted a meta-analysis to investigate the best approach in the treatment of 
refractory anxiety using coordinated anxiety learning and management (CALM) tool. Similarly, 
Bandelow et al. (2015) explored the application of Hamilton anxiety rating scale (HAM-A) in 
managing GAD among patients who had misused benzodiazepine. Similarly, Carr et al. (2019) 
also conducted quality improvement project on how to implement benzodiazepine protocols 
using 3-month PDSA improvement cycle. 
 The literature also includes clinical guidelines for the management of panic disorder and 
GAD by the National Institute for Clinical Excellence (2004). The American Psychiatric 
Association (2008) also published guidelines on the treatment of patients with panic disorder 
suggests the use of tricyclic antidepressants. The literature supports the implementation of EBP 
in de-escalation of benzodiazepine among patients with GAD (Bandelow et al., 2017; Carr et al., 




Proposed Evidence-Based Intervention 
The purpose of this DNP project is to implement a guideline compliance program that 
assist in helping providers appropriately prescribe and/or de-escalate benzodiazepines use. The 
aim is to address the problem of benzodiazepines misuse associated with a lack of knowledge of 
the risks related to this class of medications and using the appropriate guideline to treat patients 
with GAD.  The proposed intervention involves educating prescribers and designing and 
implementing an evidence-based reference card with guidelines for treating adult patients with 
GAD. 
Review of Literature  
An in-depth literature review was conducted to answer the research question, “Among 
adults with general anxiety disorders (P), does implementation of de-escalation benzodiazepine 
program used as a guideline to safe treatment of anxiety (I), lead to reduce benzodiazepine use, 
adherence to healthy lifestyle, maintance of sobriety (O) in eight weeks (T)? 
 A search of the nursing literature utilizing data bases was initiated.  Databases searched 
included PubMed, CINAHL, Web of Science, Medline, Science Direct, EBSCOhost, Google 
Scholar, and ProQuest. The keywords used were benzodiazepines, de-escalation of 
benzodiazepines, benzodiazepines abuse, benzodiazepines misuse, clinical guidelines for 
benzodiazepines prescription and monitoring. Over 42 articles retrieved and after reviewing 
reports, the articles that directly discussed de-escalation of benzodiazepine use in outpatient and 
inpatient settings were included. All evidence was appraised using the Melnyk -Fineout 
Overhold Rapid Appraisal Forms. In three articles randomized control trials was used, 5 articles 
non-experimental design was used while in two articles systematic review of the literature was 
conducted. Different data was used to examine regional variation in trends in the relationship 
18 
between anti-anxiety medications (SSRI), different treatments (cognitive-behavioral therapy and 
combination) and BZDs. To facilitate generalizability, only participants with DSM-V GAD were 
selected.  All studies used the instruments for measurement of anxiety.  
Relevant Studies 
Adult patients with anxiety disorder often abuse prescribed medications for their 
respective condition. A meta-analysis by Bandelow et al. (2017) examined pre-post effect in 
relation to changes in size prior and after commencing treatment with medications and 
psychotherapies. A total of 35,000 patients aged between 7 years and 65 years were included as 
an ideal sample population for the psychotherapy studies. The result would later indicate that 
individuals within this group exhibited less damaging effect within an outpatient setting that has 
been taking BZDs for a short time. The Hamilton Anxiety Rating Scale (HAM-A) was also 
utilized as an ideal diagnostic measure and analysis based on frequency and relative risk. The 
findings recorded indicated a significant decrease in anxiety levels after the implementation of a 
drug treatment regimen and CBT. In relation to the synthesis of this scholarly work, the evidence 
was robust and supported the treatment of GAD. The authors present the evidence that strategies 
other than BZDs are being used to treat anxiety and they substantially decrease levels of anxiety 
among adult patients. It would, therefore, go a long way in contributing to the application of 
tools and large data in the diagnosis and rating of patients with anxiety and on benzodiazepines 
as depicted in Table 2 (Appendix A).  
Using meta-analysis methodology, Roy-Byrne (2015) sought to determine the best 
approach in the treatment of refractory anxiety over 12 months, 69 participants were receiving a 
different treatment for anxiety. The CALM tool was ideal for this study, especially in relation to 
identifying the most appropriate treatment options for individuals with anxiety. Similarly, to the 
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other studies, negative results of BZDs including high risk for dependence   are explained along 
with a need to use strategies for improved assessment to determine best practice. The analysis 
was based on the actual frequency of using benzodiazepines, its relative risk, and other available 
options. The strength of the evidence provided was on its focus on multiple treatment options 
and the amalgamation of CBT as depicted in Table 2 (Appendix A). Authors present evidence 
that the clinician should proceed by exploring combination treatment with multiple modalities 
(this has usually been tried already) and then either multiple novel medications, more aggressive, 
longer-duration CBT, or a switch to another psychotherapeutic modality such as IPT or 
psychodynamic psychotherapy as depicted in Table 1 (Appendix A).    
In a meta-analysis and a systematic review, Bandelow et al. (2015) compared the relative 
efficacy of pharmacological intervention as opposed to a combined treatment for GAD, panic 
disorder (PD). A total of 37,333 participants took part in the study which also included 
randomized trials with adults receiving pharmacological treatment for GAD. Similarly, the 
HAM-A was applied to this case of data analysis conducted based on frequency and relative risk. 
The preliminary findings recorded in this study indicated a lower level of anxiety after the 
implementation of a treatment plan with a selective serotonin reuptake inhibitor (SSRI). The 
study’s transparent design, analytic approach based on the HAM-A scale and the presence of a 
predefined question, later answered appropriately, were some of the major strengths noted during 
the initial appraisal as depicted in Table 2 (Appendix A). However, the researchers’ overreliance 
on a single viewer framework in the evaluation of published literature and the presence of mixed 
treatment meta-analyses were among some of the major weaknesses noted. This was further 
compounded by insufficient data when conducting respective statistical analyses. The authors 
provide evidence that selective serotonin reuptake inhibitors (SSRIs) are the most effective 
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treatment option for adults with anxiety and can be used as first line treatment. Therefore, steps 
to de-escalate BZDs use are taken by prescribing SSRIs (Bandelow et al., 2015). 
A meta-analysis by Platt (2016) sought to ascertain the impact of using BZDs versus 
alternative treatment options. A total of 12 studies were appraised, in addition to the participation 
of 1338 adult patients with anxiety over a six-month period. The GAD, PDSS, and SPIN were 
ideal tools for this study as depicted in Table 2 (Appendix A). The analysis was based on the 
actual frequency of using benzodiazepines. The findings indicated that natural non-chemical 
anxiolytic treatments are available and can be safely recommended for patients. The strength of 
this study was in its use of empirical data while its weakness which went a long way in painting 
an elaborate picture of benzodiazepine addiction as a major public health issue. Similarly, to the 
other studies, contribution is to support that overuse of benzodiazepine drugs to treat anxiety, 
mood, and sleep disorders are a growing problem in clinical practice (Platt, 2016). 
Utilizing a randomized control trial, Shinfuku (2019) investigated the short-and long-
term effects of benzodiazepines. A total of 1228 participants took part in the study over a 13-
week period. IV1 Tx, no Tx recorded for IV2, other Tx for IV3, and the level of anxiety for 
DV1. Similarly, to other studies, HAM-A tool was implemented to gauge the efficacy of 
treatment option and an accompanying analysis based on relative risk and frequency of use.  
After the first 8 weeks, it was discovered that no significant differences existed between 
prescribing benzodiazepines and antidepressants. The study was well designed, with accurate 
findings which supported the proposition. However, the limited number of studies used meant 
that further investigation on the role and safety of benzodiazepines. This study supports that 
long-term BZDs use is not endorsed in the treatment for anxiety disorder but is prevalent in the 
real-worlds clinical settings and presents gaps in evidence-based practice. It also presents 
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evidence that alternative interventions such as CBT, non-BZD medications have better outcomes 
in lowering anxiety level and de-escalating BZDs use as depicted in Table 2 (Appendix A). 
          Using quasi-experiment design, Carr et al. (2019) conducted quality improvement project 
that encouraged patients to commit to deprescribing BZD protocols and improve upon current 
benzodiazepine deprescribing archetypes within 3-month PDSA improvement cycle. Strength of 
the study are high specificity, procured optimal outcomes, relevant information regarding 
implementation of deprescribing protocols for adults (65+ years of age). Small sample size and 
data is limited to adults over 65 years of age. Information can be used to design and conduct 
future studies with larger sample size and population. Data alludes to potentially promising 
deprescribing protocols and provides insight into commonly encountered complications. 
Information can be used to design and conduct future studies with larger sample size and 
population. Data alludes to potentially promising deprescribing protocols and provides insight 
into commonly encountered complications. Authors present evidence that medication review, 
patient education, brief counseling helped empower patients and deprescribing BZDs was 
effective strategy to de-escalate BZDs use as depicted in Table 1 (Appendix A). 
Given the significance of drug dependence, Liebrenz et al. (2015) conducted a qualitative 
study with 41 adults that were meeting criteria for BZD-dependence according to the 10th 
revision of ICD-10. Highlighting patients’ self-reporting beliefs and perceptions on factors 
contributing to their initial BZD use for mental disorders, as well as treatment preferences and 
how they obtained BZDs. Primarily conducted to document patients’ thoughts and perceptions 
about BZD use; assess trends and data to note applicability and utility value to development of 
refined comprehensive treatment planning. Strength of this study aggregate unadulterated 
subjective data reports from patients with thoughtful reflections on their reasons of BZD use. 
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Weakness was the limit in its ability to provide high-quality data with robust utility value; there 
is an inability to make evidence-based inferences after completion of the study. Participation was 
voluntary; therefore, there is an immediate inherent bias.  Subjective patient reports provide 
assessment data pertinent to constructing future hypotheses, research studies, and treatment 
plans.          
It is acute need of the time to identify BZD misuse risk factors prior to prescribing. 
Health care professionals are required to use innocuous alternatives, and to make fitting 
interventions to decrease the ongoing abuse. Since BZDs since have a place in therapy 
interventions of GAD, education of patients on the risks is tasked with a prescriber. Treatment 
plans and monitoring measures for abuse of substance need to be carefully implemented in the 
future with the aim of reducing inappropriate prescription rather than targeting all prescriptions. 
This will maintain accessibility to applicable patients with appropriate medical use symptoms. In 
this case, health care professionals must also keep themselves abreast with latest developments, 
abuse patterns and trends to divert abuse of prescribed substances. 
Synthesis of Literature 
 Although the reviewed experimental studies (RCTs and quasi-experimental) had a wide 
range of similarities in their proposed EBP intervention, they still possessed marked differences 
which were unique to each study. Bandelow et al. (2017) and Shinfuku (2019) randomly selected 
large sample sizes ensuring generalization of their findings while Liebrenz et al. (2015) and Carr 
et al. (2019) had smaller sample sizes. Participants in all the studies were classified as adults 
between the ages of 18 to 65-70 years except for one study that focused on pregnant women. The 
inclusion criteria of all the studies stressed on and underlying diagnoses. Although an underlying 
inclusion criterion for participants in all the studies was receiving antianxiety medication and did 
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not specify other possible conditions contributing to anxiety. All studies used for this literature 
review adopted the same EBP intervention which stressed on the effect of psychoeducation on 
mediation choices among participant to decrease benzodiazepine use.  Through psychoeducation 
on lifestyle changes among participants to decrease benzodiazepine use, all studies reported that 
participants experience less anxiety, higher productivity, and overall feeling healthy after they 
started exercising, meditating, walking, and started psychotherapy. Participants in the RCT study 
by Shinfuku (2019) were requested to frequent toxicology test to rule out BZDs use.  Increased 
knowledge on available treatment options and healthy lifestyle choices was however noted in all 
participants of the various studies. A total of 11 guidelines were reviewed with a wide range of 
similarities in their proposed evidence-based projects (EBP) intervention, the studies still 
contained marked differences which were unique to each study. Some studies (Schmitz 2016) do 
not associate the role of gender in distinguishing abuse of BZDs. Whereas APA guideline 
suggests that females are not only more likely to abuse when they have a history of substance 
abuse but rather females are also susceptible to boss density loss from the use of SSRIs. All 
guidelines recognize the need for second- and third-line prescriptions if the first interventions 
don’t show promising results.  
Participants in all the studies were classified as adults between the ages of 18 to 65-70 
years except for the study of (Rubinchik, et al. 2005) which sampled adults before the age of 49 
since the focus of the study were female patients of GAD who were also pregnant. This study 
also examined children of up to 18 months of age who were exposed to BZDs interventions.  
The addition criteria of all the studies stressed on and underlying diagnoses. Although an 
underlying addition criterion for participants in all the studies was receiving antianxiety 
medication and did not specify other possible conditions contributing to anxiety. All studies used 
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for this literature review embraced the same EBP intervention which stressed on the effect of 
psychoeducation on mediation choices among participant to decrease benzodiazepine use.  
Through psychoeducation on lifestyle changes among participants to decrease benzodiazepine 
use, all studies reported that participants experience less anxiety, higher productivity, and overall 
feeling healthy after they started exercising, meditating, walking, and started psychotherapy. 
Guiding Theory 
The theoretical framework that would assist with implementation of this evidence-based 
project (EBP) is Kurt Lewin’s Change Theory.  This theory was first introduced in the 1940s.  It 
provides a ground for effective implementation of change by a person or an entire group of 
people (Curtis et al., 2016).  For a patient with a new or currently existing diagnosis of anxiety to 
adapt to changes in medications and lifestyle through psychoeducation, going through a 
transformational change would need to occur.  This change process goes beyond the superficial 
alterations which are easily noticeable to address the mental and emotional need to attain 
wellbeing.   
Lewin’s change theory is based on three basic core concepts. First one is ‘driving force’, 
the second is ‘restraining force’ and equilibrium being the third, which are simply referred as 
unfreeze, change, and refreeze (Lewin, 1999). In this model work is divided into three 
categories. Each category represents a step. Step one is Unfreezing. The subjects are made to 
unlearn their old habits. Different methods of perspective changing, and unlearning can be 
applied according to the subject. In the change phase new habits are introduced to the subject. In 
this stage compatibility of subject with the new method is also recorded. If this change process is 
successful, we enter the third and final stage that is refreeze. In this stage we try to make this 
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newly introduced habit a permanent habit. This will require periodic follow ups and deadline 
setting. 
Lewin stated that while driving force tends to move in the directed direction, restraining 
forces which are also present, act as a barrier in the path of our new change process. The 
interaction of these forces usually causes imbalance however when restraining forces become 
equal to driving forces, equilibrium is reached and as result no change takes place. Recognizing 
the restraining forces timely, and successfully decreasing them is essential to achieve the desired 
effect of the newly introduced change. Prescriber should reinforce a patient’s desire to obtain a 
healthy mind that will be used as a driving force for treatment while discouraging misuse of 
benzodiazepines which acts as a restraining force. Using the principles of Lewin’s Change 
theory, prescribers should provide the patients with tools and knowledge to learn and apply this 
knowledge to get healthier lifestyle. This helps patients to be less dependent on medication while 
managing their anxiety and staying benzodiazepine free. 
In 1999 Lewin and Gold explained that it is necessity for any social change to work that 
the patients should be able to reference whenever needed, by ensuring reinforcements and follow 
ups. Properly and systematically educating patients about danger of prescribed benzodiazepines 
medications and alternative options to treat anxiety through psychoeducation can potentially 
bring people towards healthier lifestyle and navigate towards protecting each other and 
enhancing overall patient outcomes with decreasing benzodiazepine crisis.  
Application to the DNP Project 
The de-escalation benzodiazepine program patterned through Kurt Lewin’s Change 
theory contributes to the stages that the patient with anxiety was going through during the 
project. Lewin’s complex processes were explained in three major stages of change. These stages 
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were referred to as unfreezing, moving, and refreezing; that an individual went through to 
achieve lasting change (see Appendix B).  
In the unfreezing stage of change, the prescriber helped the patient, who may be misusing 
benzodiazepine, to understand the value and need for change, through detailed education (Lewin, 
1999). The first stage, unfreezing, tends to decrease hostility to change from an inadequately 
educated patient about the need for change. This is a significant phase in the change process as it 
predicts the patient’s reactions towards the change and points out if the process needs to be 
revised. During this phase, patients were educated on the negative long-term benzodiazepine use 
and other alternative strategies and medication regimens available should be shown to them. The 
potential risks of benzodiazepines were discussed thoroughly with patients because it is very 
necessary that the patient understands the process and importance of this project. To make sure 
that the patient can understand the rationale behind the initiation of this change process, effective 
communication crucial in this stage. The prescriber assessed the patient’s currently used 
medications, his habits and any factors contributing to their anxiety.  
After educating about the need for change and benzodiazepine misuse during the 
unfreezing stage, the second stage, the moving stage, focused on developing a favorable 
environment for change to occur (Curtis et al., 2016). In this stage, the prescriber introduced or 
reinforced healthier options to treat anxiety which guided patients to meditation, exercise, 
therapy, and prescribed alternative anti-anxiety medicines.  
In the final stage of change theory, refreezing, stakeholders decided whether the change 
was successful or not while discussing challenges encountered or still facing, areas requiring 
improvement as well as planning for the way to move forward (Curtis et al., 2016). After making 
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 The project implementation occurred in an outpatient behavioral health clinic in Las 
Vegas, Nevada, in the summer of 2021. The clinic provides care to over 6,000 clients yearly with 
diverse mental illnesses including GAD. The team at the mental health clinic included 
psychiatrists, doctoral and masters prepared psychiatric nurse practitioners, medical assistants, an 
office manager, laboratory service personnel, information technology (IT) personnel as well as 
accounting/billing department.  The clinic serves clients that over the age of 18 years to geriatric 
population. The common diagnoses managed at the clinic include bipolar disorder, depression, 
schizophrenia, substance abuse, posttraumatic stress disorder, attention deficit hyperactive 
disorder and anxiety disorder.  
             All patients receiving treatment at the clinic had some form of private, state, or federal-
funded health insurance while others are private pay clients. Some of the clients are homeless 
residing at shelters who have health insurance coverage. The clinic is conveniently located on the 
public transportation route with primary care outpatient clinics as well as other healthcare 
facilities within proximity. The setting was selected for implementation of the project because of 
patients’ subjective reports and objective assessment of benzodiazepine induced side effects 
including dependence as well as willingness to change to alternative strategies to treat anxiety.  
Stakeholders 
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The Calm Clinic in Las Vegas, Nevada is part of a larger of franchise of health facilities. 
In this regard, organization stakeholders are the clinic management lead by the board and the 
chief executive officer. The management was expected to allow for the project to take place at 
the clinic and use of the resources. The organization management was also expected to 
implement the EBP findings if they meet outlined thresholds.  
The interprofessional team at the practice site included psychiatrists, doctoral prepared 
nurse practitioners, medical assistants, an office manager, information technology (IT) personnel 
as well as accounting/billing department. Team members participated in this project according to 
their scope of practice and job description. The psychiatrists and other nurse practitioners 
referred patients, who were prescribed BZDs medications, to the Principal Investigator (PI) who 
was responsible for providing psychoeducation. Scheduling of participants for this project was 
the responsibility of the medical assistants. The preceptor for this project served as a resource for 
the PI while Information Technology (IT) personnel assisted in retrieving a list of patients with 
anxiety that are prescribed benzodiazepines from the electronic medical records (EMR) in the 
clinic. Project participants constituted an important group of this project’s stakeholders whose 
understanding and implementation of the psychoeducational intervention were evaluated at the 
end of the entire project. 
The major stakeholders within the ambulatory care setting who benefited from de-
escalating benzodiazepine use program involved patients with anxiety, their families, healthcare 
providers involved in care, interdisciplinary healthcare team, insurance companies, and 
pharmaceutical companies. Some of the major drawbacks to integrating de-escalating 
benzodiazepine use within outpatient psychiatric care settings stem from being unaware of 
existing drug use, obtaining benzodiazepine from other sources, and receiving care from other 
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clinics with mental health services (Bersani et al., 2017). De-escalating benzodiazepine use in 
general has been supported by many professional groups.    
DNP-prepared nurses or Advance Practice Nurses (APNs) with a specialization in 
psychiatry are well trained and well vexed in identifying, diagnosing, treating, and managing 
mental health disorders including GAD within the outpatient care setting. Although there were 
different avenues to integrate mental health services, the most beneficial approach is 
coordination of care (Olfson, 2016).  In this way, patients with GAD who need a proper 
assessment using evidence-based practice tools, are directed to a clinic where the continuation of 
care can be provided (Olfson, 2016).  Some of the disadvantages to this method of care delivery 
may be lack of reliable transportation to appointments, high copays, and conflict in schedule. 
Olfson (2016) describes a model of care where providers can receive specialized training in 
mental health disorders such as anxiety and continuation of holistic care, so continuation of care 
is smooth. In this business plan, the project is an advanced step further and instead of training 
Primary Care Providers (PCPs), DNP-prepared Psychiatric Mental Health Nurse Practitioners 
offer mental health services with de-escalation of benzodiazepine use and their follow up 
appointment. This decreases continuation of the same medication regimen that involves 
benzodiazepines, decreases risk for misuse, costs of care, and improve patients’ outcomes.  
When de-escalation of benzodiazepine use programs are integrated into the treatment plan of all 
the patients with diagnosis of GAD and BZDs use, there is a multidisciplinary team involved and 
that decreases the risk for polypharmacy as well as provision of care to ensure that mental care 
needs are met without gaps. 
Organization Assessment 
 Regarding informatics, the clinic has integrated various technologies into its operations. 
30 
For instance, there are electronic medical records for storing patient records and the use of 
computerized physician order entry. In line with the project purpose the clinic uses electronic 
prescription which will be used to retrieved records to evaluate the project progress.  
 At the clinic there is a holistic approach to delivering services to patients. The clinic 
leadership ensures that there are adequate human and fiscal resources to deliver feasible services 
in line with federal requirements and existing clinical guidelines. Also, there is coordination and 
collaboration between health care practitioners involved in patient care.  
 Strengths. The clinic has an organization where it is dedicated to evaluating existing 
ways of delivering services and improving them where there is need. Also, the clinic leadership 
has consistently supported and encouraged implementation of EBP which they are convinced 
about positive effects on the organization. The clinic has qualified and experienced team of 
psychiatrists who implemented the project.   
 Weaknesses. Whereas the organization is devoted to improving of services and 
implementing of EBP, only a few have been conducted at the site and their findings 
implemented. The organization has set a high threshold for approving EBP projects at the site 
and adopting their findings.  
 Opportunities. Providing an intervention to reduce the misuse of BZDs leads to an 
improvement in patient outcomes and have positive effects on the organization. The clinic 
attends to patients who have been diagnosed with GAD hence there is an opportunity to de-
escalate the use of BZDs.  
Threats. One threat was that the project was affected by COVID-19. There 
were regulations that limit physical contact and there was a chance of a ban on 
movement. This could lead to project discontinuation or postponement until such a 
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time it is feasible to implement as conceptualized.  
Congruence 
  Risks associated with using benzodiazepines raise concern among patients and 
healthcare providers. Internal evidence such as patient’s clinical status/circumstances, patient’s 
preferences, and outcomes of quality improvement projects were considered during clinical 
decision making (Bersani et al., 2017). For this project, in addition to patients’ subjective reports 
of benzodiazepine dependence and exacerbation of symptoms of anxiety, underlying disease 
processes related to prescribed benzodiazepines, patient’s current underlying factors, lifestyle, 
stressors, dietary habits, medical conditions as well as physical activity level were analyzed prior 
to delivery of psychoeducational intervention and decreasing or discontinuing benzodiazepines. 
This internally generated data was compared with national and global statistics of the problem of 
benzodiazepine use crisis, fetal risks of its misuse and its impact on society.  
The project took place at the Calm Clinic that is a Limited Liability Company (LLC) 
where patients with mental health needs received services at the same location as their outpatient 
mental health clinic-Anywhere Clinic. Alterations were made to the initial introduction of the 
program to the potential clients who are in the mental health clinic. The practice is operated by 
board-certified Psychiatrist Mental Health Nurse Practitioner and includes services offered by a 
board-certified DNP-prepared psychiatric nurse practitioner. Calm Clinic as a mental health 
practice was originally formed by Psychiatrist, Dr. Sam Zand in 2017. The main mission of the 
practice is to help patients to maintain mental health in a compassionate and professional 
environment. Their philosophy is to allow patients having a healthy and enjoyable life with an 
organizational goal for the team to provide a high quality, patient-centric, and safe care for the 
patient who suffer from anxiety and risking benzodiazepine dependence.  Additionally, 
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decreasing benzodiazepine prescribing and therefore use by implementing de-escalating 
benzodiazepine program and education (Johnson & Garvin, 2017).  
Statement of Mutual Agreement 
 The clinic’s management and practitioners working at the facility have agreed to 
collaborate with the DNP student towards the implementation of this project. The management 
has permitted the student to implement the project at the facility towards improving 
benzodiazepine prescription practices among the practitioners at the clinic.  
Methodology 
Aims & Objectives 
 The purpose of the project was to implement a guideline compliance program that assists 
in helping providers appropriately prescribe and/or de-escalate benzodiazepine use.  Through this 
program, prescribers were challenged to better utilize evidence-based practice guidelines when 
providing care for adults with GAD via a reminder card.  This helped to reinforce best practice 
and ultimately reduce long-term risks to patients. Specific goals were to adhere to guidelines, de-
escalate benzodiazepine use (when appropriate), and promote sobriety (T) over an eight-week 
time frame. 
Objectives: 
I. Provide education to prescribers to reinforce evidence-based guidelines in treatment of 
GAD and reinforce this teaching via a reminder card summarizing the guidelines for 
GAD on one page. 
II. Evaluated Outcomes: 
a. Compliance Outcome 1: Ensure that 100% of patients were offered a non-
pharmacologic adjunctive therapy at each visit 
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b. Compliance Outcome 2: Ensure that 100% of patients receiving appropriate 
medications either: 
i. If Benzodiazepine Dependent: offered opportunity to de-escalate at each 
visit. The goal was to reduce the benzodiazepine prescriptions by 50% or 
more. 
ii. If Benzodiazepine Naive: offered alternative or appropriate use of 
benzodiazepine per the GAD guidelines.  
c. Health Outcome (Anxiety): The anxiety level of all the patients were monitored. 
The goal was to have reduction of anxiety from baseline, though the response may 
be very individualized. 
d. Process Outcome 1: At least 75% of the prescribers at the Calm Clinic reported 
use of the reminder card while treating their patients with GAD.  
e. Process Outcome 2: 100% of providers completed the program evaluation for the 
purpose of feedback and improvement. 
Implementation Framework 
The Plan-Do-Study-Act (PDSA) cycle served as the guiding framework to evaluate 
current guidelines used in screening, diagnosing, and treating adults with GAD (see Figure 1). 
The PDSA cycle is an iterative, four stage problem solving model used for improving a process 
or carrying out a change (Coury et al., 2017). It is often used in quality improvement projects, 
where the aim is to improve the quality of care through collaborative changes in practice.  
Step 1: Plan 
During Step 1, the DNP student recruited a team comprised of relevant stakeholders 
required to implement the change – 6 clinicians and administrative staff. Then, an initial meeting 
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to discuss the current treatments for patients with GAD, educate on benzodiazepines, and 
introduce a reminder card with the preferred guideline. The primary investigator discussed the 
importance and benefits of using GAD-7 to measure anxiety levels objectively, SSRI as first-line 
treatment v benzodiazepine, CBT as adjunctive therapy, and importance of offering the 
opportunity to de-escalate current benzodiazepine use. All relevant partners were notified of the 
study prior to the start date.  
Step 2: Do 
Step 2 involves implementing the reminder card. Three providers recruited patients to the 
project who are being treated for Generalized Anxiety Disorder. The providers utilized evidence-
based guidelines and the card to treat the patients. Over a eight-week period, data was collected 
to determine their level of success with project outcomes (previously listed). Patients were 
assigned a random number for de-identification and chart reviews were completed 
retrospectively to evaluate project outcomes: 1) offered a non-pharmacologic adjunctive therapy 
at each visit; 2) offered appropriate medication therapy (naive v dependent); 3) objective 
evaluation of anxiety via GAD 7; and 4) overall number of benzodiazepine prescriptions used. 
Step 3: Study  
During Step 3, the project leader hosted discussion to gather feedback from the providers 
who used a quick reference card while treating adult patients with GAD, focusing on barriers and 
facilitators to implementation. To understand if the education and card resulted in an 
improvement the number of BZDs prescriptions, therefore, de-escalation of benzodiazepine use 
were assessed. In tandem, discussions about experience of using the card informed about needed 
improvements in using the guidelines.  
Step 4: Act 
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Step 4 involved a final assessment of the process and thoughts on how to move ahead. 
The Act stage in this process for improvement was two-fold. Using the information and 
revelations assessed in the study phase, the team updated and altered the plan for change to build 
on change facilitators and address barriers to implementation. This step also involved 
documentation describing the outcomes of this process, including publication of results, so that 
others can evaluate the evidence generated here and consider changes in clinical practice. The 
second part of this phase was to reflect and create documentation that describes the outcome of 
this process so that others can see the outcome of this study and make their own plans for 
change. 
Population and Setting  
The population targeted in this change project was prescribers who are physician 
assistants and nurse practitioners treating adult patients diagnosed with GAD. This study 
occurred at the Calm Clinic in Las Vegas, Nevada. The clinic was responsible for providing 
outpatient mental healthcare for adults. Using the evidence-based practice guidelines to treat 
patients diagnosed with GAD while de-escalating benzodiazepine prescribing was a critical goal 
for the clinic.  
Recruitment Method  
 Following IRB approval of the project, the providers utilized the card. After 8 weeks, the 
patient charts were reviewed. The charts were selected if the patient was 18 years old and older, 
diagnosed with GAD, and being treated at the Calm Clinic. Patients were English-speaking 
(Appendix H). The goal was to recruit 30 patients minimum, 50 maximum per provider (6) over 
a period of 8 weeks. 
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IRB Submission Process & Ethical Considerations 
 A review application for Internal Review Board (IRB) approval was obtained from 
Eastern Kentucky University (EKU) before the beginning of this project. After receiving 
approval from EKU’s IRB.  
Though the patients were treated for a mental illness, the goal of this project was to help 
providers comply to standards of care. Therefore, there was no increased risk to the patient. It is 
important to note also, that ultimately the decision to prescribe medication was made between 
the provider and with the input of the patient. Especially in the case of de-escalating use of 
benzodiazepine use in patients already using the medication, the goal was to offer the 
opportunity to de-escalate. Patients may choose their own path/therapy with the supervision of 
the individual medical provider. The reminder card was designed to merely “remind” the 
provider of best practice. The patient chart review was purely retrospective. 
Instruments 
Demographic & Pre-Intervention Form 
 The providers involved in the project were asked to complete a simple demographic form 
that describes their age, medical training, and experiences with benzodiazepine prescribing. The 
goal was to describe the population and document their input and perspective (Appendix C). 
Chart Review 
Patient information were organized by provider. Under each provider, the patients were 
assigned a random number for chart review and the master list linking the provider and patient 
maintained at the Calm Clinic by the primary investigator in the secure electronic health record. 
Each chart was reviewed to ensure: 
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• Offered of a non-pharmacology therapy at each visit for GAD 
• Offered of appropriate medication therapy and/or opportunity to de-escalate 
• Assessed anxiety using GAD-7  
• Number of overall benzodiazepine prescriptions per provider pre and post 
intervention 
GAD-7 Scale 
 To measure the anxiety level of the patients, pre-intervention and post-intervention, as 
well as during the 8-week implementation time, GAD scale-7 or GAD-7 scale was used (see 
Appendix D). This tool is a self-reported questionnaire that screens the severity of the anxiety of 
the patient.  There are seven items or questions in the GAD-7 scale. The GAD-7 items include: 
1) nervousness; 2) inability to stop worrying; 3) excessive worry; 4) restlessness; 5) difficulty in 
relaxing; 6) easy irritation; and 7 fear of something awful happening (see Appendix D). 
Assessment is indicated by the total score, which is made up by adding together the scores for 
the scale of all seven items. It measures the severity of different signs of GAD with each having 
some assigned points. The questions included are regarding excessive worry, easy irritation, fear 
of something awful happening, difficulty in relaxing, inability to stop worrying, nervousness, and 
restlessness. Each of these measures has a score rating of 10, and together they make total of 70 
points. The specificity value is 0.82 and sensitivity value is 0.89 to identify as GAD diagnosis. 
The GAD-7 scale was developed in 1990s, and currently it is the most used tools to assess the 
anxiety level for GAD (Pascal et al., 2017).  
Process Evaluation 
 During this project, a data collection form was provided to participants on the first and 
last day of the follow up appointments. The form collected information on anxiety level and 
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number of benzodiazepine prescriptions before and after starting the quick reference card use.  
Participants also completed a weekly log, during the 8-week of project, which tracked their 
BZDs scripts and patients GAD scores (see Appendix G).  
Data Analysis, Security, and Storage 
 Only de-identified patient data was extracted during chart review. The chart review 
spreadsheet was kept locked in the office of the primary investigator at the Calm Clinic. After 
three years it will be destroyed as per EKU IRB policy.  
 Data was analyzed in chart review using measures of central tendency – mean, median, 
and mode. A paired sample, t-test was used to compare GAD-7 scores pre and post intervention 
for each domain. Cohen D efficient was used to determine overall effect.  The process evaluation 
form was reviewed by two reviewers and coded for themes. 
Timeline of Project Phases 
Recruitment period of participants occurred approximately 7 days prior to the beginning 
of this project (see Appendix J). The eight-week de-escalating benzodiazepine project was 
conducted in the clinic within an eight-week timeframe while still preserving the fundamental 
principles of the project.  Participants reported results from appointments weekly, for eight-
week. The participants were established prescribers that work at the Calm Clinic.  During the 
first meeting with the project leader, participants provided general information about the project 
and all guidelines on quick reference card.  The Medical Assistant (MA) assisted with data of the 





Anticipated Implementation Barriers 
 The project sample size represented might be a small fraction of the target patient 
population which could have benefited from this project. The eight-week timeframe for project 
implementation and evaluation might not be adequate to assess the long-term use of quick 
reference cards by providers. Participants’ personal assessment of using quick reference cards as 
well as alternative strategies to manage anxiety might pose a limitation to the project due to 
possible discrepancies in reporting. The community impact of the COVID 19 pandemic caused 
anxiety among patients might be leading to lower involvement in the project at the end due to 
underlying medical conditions which affected project sample size.  
Results 
The IRB approved the project on 10/08/2021. Recruitment of providers began 
10/08/2021. A total of 6 (N=6) participants who were Mental Health Nurse Practitioners 
completed the pre and post-test assessment. There were 3 females and 3 male participants within 
the age range of 30 to 50 years of age: with a mean age of 36.  
Compliance Outcomes 
To assess compliance outcomes patient chart audits were completed anonymously and 
with permission of patients’ provider. In total of 69 patients’ charts were reviewed. The charts 
were audited to determine if outcomes were met. 
Outcome 1: Charts were reviewed (N=69) and all the patients were offered CBT, 
exercise, meditation during the first appointment as a baseline and moving forward, continuing 
to monitor for 8 weeks. The goal to offer 100% of patients a non-pharmacologic adjunctive 
therapy at each visit was fully met. 
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Outcome 2: Benzodiazepine Prescriptions. The goal of this outcome was to ensure that 
100% of patients received appropriate medications. Over the 8-week period, 16 benzodiazepine 
prescriptions were written for the selected sample of patients (N=69). Of these prescriptions, 
n=16 were given to the patients who were already using benzodiazepines, n=2 were given to the 
patients who were benzo naive. The average number of benzodiazepine prescriptions written to a 
group of 69 patients before introducing the quick reference card was 18 that included 4 
prescriptions for benzo naïve patients and 14 for the patients who have already used the 
benzodiazepines. This indicates decrease in benzodiazepine prescriptions by 11% over the 8-
week period.  The goal to reduce prescriptions by 50% was not met, however, the PI intends to 
monitor the data.  
The documentation in the chart indicated that 100% of these patients (N=69) were 
offered the opportunity to de-escalate benzodiazepine use by decreasing doses, alternative 
medications, psychotherapy or were prescribed medications according to guidelines, therefore, 
the goal of providing 100% of patients appropriate medications was met. This outcome goal was 
fully met. 
Health Outcome: The anxiety level of all the patients (N=69) were monitored. The goal 
was to have overall reduction of anxiety in a group after reinforcing guideline adherence. The 
overall average on GAD-7 pre-intervention was 15.83 among all participants. The overall 
overage post-intervention was 10.90 among all participants.  When analyzed, a paired sample t-
test demonstrates a p -value of <0.001 which indicates that statistical significance was met.  The 
finding was clinically significant because demonstrated decrease in GAD-7 scores when 
guidelines were followed by prescribers. The Cohen’s d of (68) which indicated a large effect. 
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Process Outcomes 
             Outcome 1: Use of Guidelines.  At least 75% of the prescribers reported use of the 
reminder card while treating their patients with GAD. Collectively, 5 out of 6 participants 
(83.33%) reported a consistent use of a quick reference card, 1 participant (16.67%) reported not 
being consistent with using the card. 
Outcome 2: Program evaluation. A post intervention evaluation form was completed 
by all six participants on the last day of the group sessions. All participants (N=6; 100%) 
reported the sessions provided an overview of the EBP guidelines to treat GAD and explained 
the risk of benzodiazepines use.  All the participants (N=6; 100%) reported the sessions provided 
tips on alternatives treatments for patients with GAD and ways on how to decrease number of 
BZDs prescriptions. All participants (N=6; 100%) reported the group sessions resulted in 
substantial reduced number of BZDs prescriptions through alternative medications and therapies. 
 
Discussion 
The findings indicated that utilizing EBP guidelines in treatments of patients with GAD 
decrease overall scores on GAD-7 and reduce number of BZDs prescriptions. Approximately 
two-thirds of patients showed improvement and recovery from their symptoms of anxiety, and 
three-quarters showed reliable improvement on symptoms of anxiety.  Several RCTs (Bandelow 
et al., 2017; Shinfuku, 2019; Liebrenz et al., 2015; Carr et al., 2019) and qualitative study 
(Liebrenz et al., 2015) support the need to utilize guidelines to de-escalate use of 
benzodiazepines in treating patients with GAD through psychoeducation enforcing using 
alternative treatments and therapy. The literature reviewed in this project highlighted the positive 
42 
impact psychoeducation which emphasized first line treatments and guidelines for GAD, 
decreased use of benzodiazepines by choosing alternative anti-anxiety medications and 
treatments (Bersani et al., 2017). The findings from this project are consistent with the literature.  
Participants reported improvement with their anxiety level as they were engaged in 
therapy and non-BZDs over the eight-week period of this project.   The finding from the project 
was clinically significant because demonstrated decrease in GAD-7 scores when guidelines were 
followed by prescribers. Results of the paired t-test, presented in Table 3, compared the pre and 
post GAD-7 scores as well as a paired sample t-test for the overall GAD-7. There was significant 
increase in pre-test score for GAD-7 (M = 15.83, SD = ± 2.74) compared to post-test score for 
GAD-7 (M = 10.90, SD = ± 4.81) (Table 3).  
Although, the goal to reduce prescriptions by 50 % was not met, 100 % of the patients 
were offered the opportunity to de-escalate benzodiazepine use by decreasing doses, alternative 
medications, psychotherapy. Based on the outcome of this project, utilizing EBP guidelines to 
de-escalate BZDs use with an emphasis on alternative medications and therapy can increase 
awareness and reduce benzodiazepine use. It also encourages behavioral changes on ways to 
manage care for patients with GAD and being prescribed BZDs.  
Limitations 
The project sample size (n=69) represented might be a small fraction of the target patient 
population which could have benefited from this project. The eight-week timeframe for project 
implementation and evaluation might not be adequate to assess the long-term use of quick 
reference cards by providers. Participants’ personal assessment of using quick reference cards as 
well as alternative strategies to manage anxiety might pose a limitation to the project due to 
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possible discrepancies in reporting. The community impact of the COVID 19 pandemic caused 
increased anxiety among patients but might be leading to lower involvement in the project at the 
end due to underlying medical conditions which affected project sample size.  
Implications 
Clinical Practice 
 The EBP project focused on educating participants on EBP guidelines that will reduce 
prescribing BZDs through psychoeducation, using alternative anti-anxiety medications, and 
encouraging therapy. The intervention was successful in improving patient outcomes as 
evidenced by the post-intervention data and is aligned with the overwhelming support for 
psychoeducational intervention in already existing literature (Bandelow et al., 2017; Carr et al., 
2019; Liebrenz et al., 2015; Shinfuku, 2019). This eight-week project although brief in time 
frame, suggested benefits for a longer duration of a similar project. The DNP-prepared nurse 
could thus play a leading role in identifying, implementing, and sustaining facility wide changes 
which would improve the overall wellbeing among the patients diagnosed with GAD.  
Policy 
At the local, state, and national levels, advocacy for legislations and programs which 
would improve health literacy through providers’ education especially among mental health 
prescribers who treat patients diagnosed with GAD to be to be considered. Programs focused on 
psychoeducation explaining the EBP guidelines to treat patients with GAD and ways to 
minimize prescribing benzodiazepines could bridge the health disparity gap among patients 
diagnosed with GAD and using BZDs. According to the American Association of Colleges of 
Nursing (AACN), one role of the DNP-prepared advance practice nurse is to become an 
innovative leader in the transformation of the current health care system (AACN, 2004). The 
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DNP prepared nurse must be prepared and ready to lead, collaborate and advocate with the goal 
of improving patient and healthcare outcomes.  
Quality and Safety 
Prolonged use of benzodiazepine among persons with anxiety and related disorder may 
exacerbate health conditions by leading to increased anxiety and increase risk for complications 
including death (Hayhoe & Lee-Davey, 2018). This reinforces the need to de-escalate 
benzodiazepine use. De-escalating the use of benzodiazepines for adults is crucial in concerted 
health promotion initiatives to promote the appropriate use of the medication, prevent harm from 
abuse, and improve patient outcomes (Suss & Oldani 2020). Healthcare providers particularly 
nurse practitioners and physician assistant play a significant role in promoting proper use of and 
in de-escalation among patients with anxiety who have misused the drug (Platt et al., 2021). This 
is achieved by implementing evidenced based practice guidelines that will reduce potential for 
benzodiazepine misuse and abuse.  
In addition to psychoeducation on EBP guidelines to treat patients with anxiety, 
healthcare providers are encouraged to routinely monitor patients at risk for benzodiazepine 
misuse and educate them about different options to treat their anxiety (Bersani et al., 2017). 
Adhering to evidence-based guidelines on appropriate screening protocol and benzodiazepine 
safety monitoring would not only decrease benzodiazepine use but eventually save lives (Bersani 
et al., 2017). 
Education 
Implementation of EBP guidelines leads to improving a quality of care and best outcomes 
for the patient with generalized anxiety, reduces cost and disparity, empowers clinicians, and 
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increases role satisfaction (Melnyk & Fineout-Overholt, 2015).  Continuity of seeking and 
implementing current best evidence practice is imperative to prevent outdated treatments for 
patients diagnosed with GAD that will lead to poor patient outcomes. The DNP-prepared nurse 
must continue to implement practice change projects, educate providers, patients and their 
caregivers, advocate policy changes that sustains EBP change and embrace new evidence to 
combat non-adherence.  It will be beneficial for future work to recognize the role of 
families/caregivers. Providing psychoeducation to the providers that treat patients with anxiety 
on the need to include healthy lifestyle changes in the lives of patients prescribed 
benzodiazepines and other anti-anxiety medications will be more effective than an individual 
session.  
Sustainability 
Long term strategies are needed to sustain a project change. Upon completion of this EBP 
change project, the PI and stakeholders at the implementation site was considering several 
approaches to sustain the positive changes that were achieved. These approaches include the 
addition of psychoeducational groups to treatment as usual for patients prescribed 
benzodiazepines and anti-anxiety medications. Psychiatrists, APRNs, and Physician Assistants 
(PA) at the clinical site recommended psychoeducational sessions about available treatments for 
generalized anxiety to patients, and front office staff have been assigned to compile names for 
the Licensed Clinical Social Workers (LCSW) who developed group sessions involving 
prescribers as well.  Participants who took part in the recently completed EBP change project 
were given the opportunity to participate in educational sessions, with the goal of reinforcing 





Collaboration among a wide range of mental health providers is planned to engage a 
larger number of participants and to implement future projects in a larger area of the community.  
Poster presentations at professional organizations for mental health providers such as American 
Psychiatric Nurses Association (APNA) Nevada chapter will be utilized to accomplish this goal.  
Psychoeducational intervention based on EBP guidelines must be added to regular appointments 
and incorporated into treatments for patients prescribed BZDs medications and alternative 
treatments for GAD. Prescribers are more likely to adhere to EBP guidelines reference card if 
they have a better understanding of GAD, options of treatments, and risks related to 
benzodiazepine use.  
Conclusion 
The consequences of misusing benzodiazepines are dire. Utilizing psychoeducation 
during treatment as usual can be an effective intervention in improving utilization of quick 
reference cards as EBP guidelines for managing patients who suffer from anxiety. 
Psychoeducational interventions are designed to impart knowledge on risks of benzodiazepine 
misuse and choosing alternative medications and strategies to treat anxiety. The pre-test and 
post-test data analysis among participants before and after the project intervention will reinforce 
that psychoeducation positively impacts lifestyle changes among patients prescribed antianxiety 
medications. Implementing the tenets of this project at the practice site as well as other 
behavioral health sites could set new standards and eventually improve overall wellbeing for 
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Appendix A 
Table 1. Hierarchy Table 
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( Liebrenz, et 
al, 2015) 
 
I X  X    
II  X     
III       
IV    X   
V      X 
VI     X  
VII       
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BAI = Beck Anxiety Inventory; CALM = Coordinated Anxiety Learning and Management; DV = 
dependent variable; EPDS = Edinburgh Postnatal Depression Scale; GAD-2 = GAD–2 items; GAD-7= 
GAD–7 items; AHM-A- Hamilton anxiety scale; IV=independent variable; NR= narrative synthesis; MA 
= meta-analysis; PDQ=Prenatal Distress Questionnaire;  PHQ-9=Patient Health Questionnaire–9; ICD-
10= International Classification of Diseases; PSWQ =Penn State Worry Questionnaire; RCT = 
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                                                                  Appendix B 
Theoretical Conceptual Framework 
 
Figure 1: Model for Improvement 
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If yes, check all that apply: 
No access to guidelines 
Personal preferences 
To assess barriers in 
prescribing benzodiazepines 
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5 Q: When you make choices to 
prescribe medications for 
GAD, what do you primarily 
base your choices on? 
Choices: 
Current patient’s medications 
Personal preferences 
Other 
To distinguish choices in 
prescribing medications 
6 Q: How often are you using 






To determinate if guidelines 
are used 
7 Q: What tools do you use in 
diagnosing GAD? 
Choices: 
To assess what tool is used 
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Beck Anxiety Inventory 
(BAI) 
Penn State Worry 
Questionnaire (PSWQ) 
GAD 7 (GAD-7) 
8 What are the challenges when 
prescribing medications to 
treat patients with GAD? 
Describe 
To allow clinicians to express 
their challenges in treating 
patient with GAD 
9 What are the most common 
strategies do you use in 
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Appendix F  
 Reference Card 
 
 
The first-line treatment and gold standard for treating anxiety is CBT 
Medications: (SSRI) escitalopram, paroxetine, sertraline, (SNRIs) venlafaxine, duloxetine 
2nd line gad maintenance: buspirone (BuSpar) 
3rd line: benzodiazepines 
Alternatives for GAD maintenance: hydroxyzine, pregabalin, quetiapine 
tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs),atypical antipsychotic medications, other medications 
used off-label, such as beta-blockers 
Lifestyle changes: Exercise, breathing techniques, meditation and mindfulness, restful sleep, avoid anxiety triggers (reduce or stop caffeine, 
alcohol, tobacco and other substances) 
How is GAD diagnosed?  DSMV-5 symptoms, difficult to control worry over 6 months: restlessness, easily fatigued, difficult concentration, 
irritable, muscle tension, sleep disturbance 
Acute GAD treatment: be 
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                                                                  Appendix I 
                          Weekly Agenda for De-escalating Benzodiazepine Use Project 
Weekly Agenda Topics 
Week 1 EBP guidelines and GAD treatment, GAD 7, 
DSM V GAD categories and proper dx, first 
line GAD tx, therapies, de-escalating use of 
benzodiazepine 
Week 2 Reporting data from appointment 
Discussion 
Week 3 Reporting data from appointment 
Discussion 
Week 4 Reporting data from appointment 
Discussion 
Week 5 Reporting data from appointment 
Discussion 
Week 6 Reporting data from appointment 
Discussion 
Week 7 Reporting data from appointment 
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Discussion 
Week 8 Chart Review 
Evaluation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
